Abstract
Viruses conditionally replicating in cancer cells form an attractive novel class of antitumoral agents. To engineer such viruses infectivity can be coupled with proteolytic activity of the target cell by modifying the envelope (Env) protein of murine leukaemia virus (MLV) with blocking domains that prevent cell entry unless they are cleaved off by tumour-associated proteases like the matrix metalloproteases (MMP). Here we show that MLV variants selectively spreading through MMP-positive cells can be evolved from virus libraries, in which a standard MMP-2 substrate peptide connecting the blocking domain CD40L with the Env protein was diversified. Passaging the virus library on human fibrosarcoma or glioma cell lines resulted in the selection of about 10 virus clones, of which the three most frequent ones were shown to become activated by MMPs and to be replication competent on MMP-positive cells only. On these cells, the selected linker peptides improved the spreading by several orders of magnitude in vitro, as well as in tumour xenografts in vivo, approaching the kinetic of the unmodified wild-type virus. The data suggest that retroviral protease substrate libraries form a potent tool for the engineering of viruses conditionally replicating in a given cancer cell type of interest.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Russell SJ . RNA viruses as virotherapy agents. Cancer Gene Therapy 2002; 9: 961–966.
Lavillette D, Russell SJ, Cosset F-L . Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol 2001; 12: 461–466.
Buchholz CJ et al. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotech 1998; 16: 951–954.
Soong NW et al. Molecular breeding of viruses. Nat Genet 2000; 25: 436–439.
Bupp K, Roth M . Targeting a retroviral vector in the absence of a known cell-targeting ligand. Hum Gen Ther 2003; 14: 1557–1564.
Buchholz CJ, Stitz J, Cichutek K . Retroviral cell targeting vectors. Curr Opin Mol Ther 1999; 1: 613–621.
Morling FJ, Peng K-W, Cosset F-L, Russell SJ . Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 1997; 234: 51–61.
Martin F et al. Retrovirus targeting by tropism restriction to melanoma cells. J Virol 1999; 73: 6923–6929.
Johnson KJ et al. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease–substrate interaction. Gene Therapy 2003; 9: 725–732.
Peng KW . Protease-activatable targeted retroviral vectors. PhD Thesis, University of Cambridge, 1997, pp 187–189.
An S, Knox KA . Ligation of CD40 rescues Ramos–Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP. FEBS Lett 1996; 386: 115–122.
Schneider RM et al. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Therapy 2003; 10: 1370–1380.
Foda HD, Zucker S . Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 2001; 6: 478–482.
Cosset F-L et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995; 69: 6314–6322.
Chen EL et al. A unique substrate recognition profile for matrix metalloproteinase-2. J Biol Chem 2002; 277: 4485–4491.
Merten CM et al. Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. J Virol 2005; 79: in press.
Woessner JF, Nagase H . Matrix Metalloproteinases and TIMPs. Oxford University Press: Oxford, 2000.
Miyamori H et al. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J Biol Chem 2001; 30: 28204–28211.
Ginestra A et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 1997; 27: 17216–17222.
Rao JS . Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev 2003; 3: 489–501.
Wang WJ, Chen-Kuo T, Kasahara N, Chen TC . Highly efficient and tumor restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gen Ther 2003; 14: 117–127.
Logg CR et al. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther 2001; 12: 921–932.
Perabo L et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003; 8: 151–157.
Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH . Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 2001; 60: 6061–6067.
Adams G, Vessilier S, Dreja H, Chernajovsky Y . Targeting cytokines to inflammation sites. Nat Biotech 2003; 21: 1220–1314.
DuBridge et al. Analysis of mutation in human cells by using an Epstein–Barr virus shuttle system. Mol Cell Biol 1987; 7: 379–387.
Folks T et al. Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci USA 1985; 13: 4539–4543.
Acknowledgements
This work was supported by the fifth framework European Community program ‘The cell factory’ to CJB and MPC, and by the ‘Nationales Genomforschungsnetz (NGFN)’ to CJB and KC.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hartl, I., Schneider, R., Sun, Y. et al. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther 12, 918–926 (2005). https://doi.org/10.1038/sj.gt.3302467
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302467
Keywords
This article is cited by
-
Antifibrotic Properties of Transarterial Oncolytic VSV Therapy for Hepatocellular Carcinoma in Rats With Thioacetamide-Induced Liver Fibrosis
Molecular Therapy (2013)
-
Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue
Gene Therapy (2008)
-
Augmented transgene expression in transformed cells using a parvoviral hybrid vector
Cancer Gene Therapy (2008)
-
Targeted Cell Entry of Lentiviral Vectors
Molecular Therapy (2008)
-
Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob
Gene Therapy (2007)